Publications by authors named "Raffaele Colucci"

Claim this Profile
U
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Raffaele Colucci

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study.
Antonio Tursi, Daniele Piovani, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Raffaele Colucci

Intest Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Raffaele Colucci

J Clin Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Antonio Tursi, Giammarco Mocci, Franco Scaldaferri, Daniele Napolitano, Rossella Maresca, Raffaele Colucci

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.
Antonio Tursi, Daniele Piovani, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Raffaele Colucci

Am J Gastroenterol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Antonio Tursi, Giammarco Mocci, Linda Cingolani, Edoardo Savarino, Roberta Pica, Raffaele Colucci

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis.
Antonio Tursi, Daniele Piovani, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Raffaele Colucci

United European Gastroenterol J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci

Inflamm Bowel Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Giammarco Mocci, Antonio Tursi, Giovanni Maconi, Giovanni Cataletti, Beatrice Mantia, Raffaele Colucci

Expert Opin Biol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome.
Giulia Fiorini, Ilaria M Saracino, Matteo Pavoni, Bruno Nipote, Raffaele Colucci

Minerva Gastroenterol (Torino)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Antonio Tursi, Giammarco Mocci, Antonio Cuomo, Antonio Ferronato, Walter Elisei, Raffaele Colucci

J Gastrointestin Liver Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Marcello Picchio, Raffaele Colucci

Gut· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease.
Giovanni Brandimarte, Giovanni V Frajese, Stefano Bargiggia, Danilo Castellani, Andrea Cocco, Raffaele Colucci

Minerva Gastroenterol (Torino)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci

Expert Opin Biol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
Antonio Tursi, Giammarco Mocci, Walter Elisei, Leonardo Allegretta, Raffaele Colucci

J Gastrointestin Liver Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Antonio Tursi, Giammarco Mocci, Roberto Lorenzetti, Leonardo Allegretta, Giovanni Brandimarte, Raffaele Colucci

Eur J Gastroenterol Hepatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
Antonio Tursi, Claudio Cassieri, Raffaele Colucci, Walter Elisei, Marcello Picchio

J Gastrointestin Liver Dis· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study.
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Maria L Annunziata, Mauro Bafutto, Raffaele Colucci

United European Gastroenterol J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis